Effects of Arabinoxylan-Oligosaccharides Compared to Other Prebiotics in Healthy Subjects

This study has been completed.
Sponsor:
Information provided by:
Katholieke Universiteit Leuven
ClinicalTrials.gov Identifier:
NCT00853034
First received: February 25, 2009
Last updated: February 26, 2009
Last verified: February 2009
  Purpose

The purpose of the study is to evaluate the effects of arabinoxylan-oligosaccharides (AXOS) on the colonic metabolism and microbial composition, and to compare these effects with the reference prebiotic fructo-oligosaccharide enriched inulin.


Condition Intervention Phase
Healthy
Dietary Supplement: FOS-IN
Dietary Supplement: AXOS
Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Crossover Assignment
Masking: Single Blind (Subject)
Primary Purpose: Treatment
Official Title: Effects of Arabinoxylan-Oligosaccharides on Colonic Metabolism and Microbial Composition Compared to Other Prebiotics in Healthy Subjects

Further study details as provided by Katholieke Universiteit Leuven:

Enrollment: 20
Study Start Date: October 2006
Study Completion Date: September 2007
Arms Assigned Interventions
Active Comparator: FOS-IN
prebiotic fructo-oligosaccharide enriched inulin
Dietary Supplement: FOS-IN

prebiotic fructo-oligosaccharide enriched inulin

intake period: 2 weeks, 1.25 or 2.50g every morning and evening

Other Name: Synergy1, Orafti, Tienen
Experimental: AXOS
arabinoxylan-oligosaccharides (AXOS)
Dietary Supplement: AXOS

arabinoxylan-oligosaccharides (AXOS)

intake period: 2 weeks, 1.25 or 2.50g every morning and evening


  Eligibility

Ages Eligible for Study:   18 Years to 45 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • healthy
  • 18-45 years
  • regular eating pattern

Exclusion Criteria:

  • gastrointestinal complaints
  • antibiotic intake
  • medication influencing gut transit or microbiota
  • abdominal surgery
  • pregnancy
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00853034

Locations
Belgium
Department of Gastrointestinal Research, Laboratory Digestion and Absorption
Leuven, Belgium, 3000
Sponsors and Collaborators
Katholieke Universiteit Leuven
Investigators
Study Director: Kristin Verbeke, PhD Katholieke Universiteit Leuven
  More Information

Publications:
ClinicalTrials.gov Identifier: NCT00853034     History of Changes
Other Study ID Numbers: AXOS 001
Study First Received: February 25, 2009
Last Updated: February 26, 2009
Health Authority: Belgium: Federal Agency for Medicinal Products and Health Products

Keywords provided by Katholieke Universiteit Leuven:
gastrointestinal effects
prebiotic

ClinicalTrials.gov processed this record on April 16, 2014